[ANMCO声明:在心脏-脏-代谢障碍中的塞马格卢提德]
Leonardo De Luca1, Claudio Bilato2, Alessandro Navazio3
1S.C. Cardiologia, Dipartimento Cardio-Toraco-Vascolare, Fondazione IRCCS Policlinico San Matteo, Pavia.
概括
作为GLP-1受体激动剂的塞马格卢提德,除了糖尿病管理之外,它还提供了显著的心脏-脏和代谢益处. 它减少心血管事件,改善心力衰竭功能,并保护糖尿病患者的脏.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
背景情况:
- 塞马格卢提德是一种类似于葡萄糖的-1受体激动剂.
- 最初用于2型糖尿病 (T2DM) 血糖控制.
- 它的治疗范围扩展到心血管,脏和代谢健康.
研究的目的:
- 审查目前关于塞马格卢提德在心脏-脏-代谢连续体中的作用的证据.
- 综合其超出葡萄糖调节的多方面的好处.
主要方法:
- 临床试验和科学证据的文献综述.
- 对心血管,脏和代谢结果的数据的综合.
主要成果:
- 塞马格卢提德可以减少超重/肥胖患者的主要心血管不良事件.
- 它改善了心力衰竭中的功能能力,并保留了喷射分数.
- 它减缓了白蛋白尿的进展,并降低了T2DM中慢性病的风险.
结论:
- 塞马格卢提德在整个心脏-脏-代谢谱中表现出广泛的疗效.
- 机制包括抗炎作用,减肥,降低血压和直接的保护.
- 它是管理相互关联的心脏-脏-代谢条件的关键药物.
相关概念视频
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
429
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
429
Drug Elimination by Renal Route: Glomerular Filtration
5.4K
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production takes place. A nephron has two main components: a renal corpuscle and a renal tubule. Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent...
5.4K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
392
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
392
Drug Elimination: Non-Renal Routes
2.3K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
2.3K


